Lupin Limited (NSE:LUPIN)

Market Cap	1.03T +3.1%
Revenue (ttm)	261.51B +18.9%
Net Income	46.45B +61.9%
EPS	101.39 +61.7%
Shares Out	n/a
PE Ratio	22.15
Forward PE	22.37
Dividend	12.00 (0.54%)
Ex-Dividend Date	Jul 25, 2025

Volume	1,104,217
Average Volume	816,658
Open	2,267.20
Previous Close	2,250.20
Day's Range	2,254.80 - 2,299.70
52-Week Range	1,795.20 - 2,299.70
Beta	0.30
RSI	69.01
Earnings Date	Feb 12, 2026

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 24,006
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LUPIN

Financial Performance

In fiscal year 2025, Lupin's revenue was 227.08 billion, an increase of 13.48% compared to the previous year's 200.11 billion. Earnings were 32.82 billion, an increase of 71.41%.